Introduction
============

Breast cancer is a heterogeneous disease, with distinct subtypes characterized by different biology and response to therapy. At least four subtypes of breast tumors have been identified by initial molecular profiling: luminal A and luminal B, which are positive for both estrogen and progesterone receptors (ER and PGR); HER2-positive and basal-like/triple-negative (lacking ER, PGR and HER2).[@R1]^-^[@R3] More recently, the claudin-low subtype has been identified among triple-negative breast cancers.[@R4] These distinct tumor subtypes present different prognosis, with the shortest survival time observed among HER2-positive and basal-like/claudin-low breast cancer patients.[@R5] Interestingly, both basal-like/claudin-low and HER2-positive tumors have proven to be particularly enriched in cancer stem cells (CSC), which are cells endowed with self-renewal and pluripotency potential.[@R6]^,^[@R7] Stem-like features may be functionally demonstrated in vitro by the ability of CSC to grow as mammospheres (MS) in non-adherent/serum-free stem conditions[@R8] and in vivo by the ability of mammospheres to generate tumors when injected at limiting dilutions in immunocompromised mice.[@R9]^-^[@R12] Indeed, the capability to generate primary mammospheres (M1) in stem conditions, and to perpetrate as secondary (M2) and tertiary (M3) spheres, is considered as an in vitro surrogate of the in vivo evaluation of self-renewal potential. The coordinated expression of pluripotency transcription factors, including POU5F1 (OCT3/4), NANOG and SOX2, has emerged as a regulatory mechanism of stem cell pluripotency and differentiation[@R13] and, indeed, these genes and their targets are frequently overexpressed in poorly differentiated breast cancer.[@R14]^,^[@R15] Furthermore, breast CSC have been reported to display the CD44^+^/CD24^-/low^ antigenic profile that correlates with resistance to conventional therapeutics.[@R16]^-^[@R18]

Beside stem-like features, basal-like and especially claudin-low tumors express mesenchymal markers typical of tumors that have undergone epithelial-to-mesenchymal transition (EMT), an embryonic trans-differentiation program reactivated in several carcinomas and correlated with tumor progression and invasiveness.[@R4]^,^[@R19] The major players of the EMT program include members of the SNAI, ZEB and TWIST family of embryonic transcription factors that, through the establishment of a complex network of interactions only partially elucidated, induce the expression of mesenchymal markers (Vimentin and N-cadherin) and the repression of epithelial molecules such as E-cadherin.[@R20]^,^[@R21]

Both EMT and elevated content of cells endowed with stem-like properties characterize aggressive undifferentiated tumors, and data suggest that certain components of the EMT program may also play a critical role in tissue homeostasis, thus linking stemness to EMT.[@R9]^,^[@R22]^,^[@R23] Indeed, growing evidence indicates that the induction of EMT results in expanded CSC populations (reviewed in ref. [@R24]). Whether, instead, the expansion of cells endowed with stem-like properties selects also for cells provided with EMT features is less established.

Based on this information, we sought to investigate whether the growth of breast cancer cells in MS-proficient conditions affects the fraction of cells displaying EMT features. To this end, we compared EMT and stem features of a series of 10 breast cancer cell lines, representative of distinct subtypes (luminal; HER2-positive; basal-like and claudin-low), grown in adhesion and in MS-proficient conditions. We found that, along with selection of stem properties, a shift toward a mesenchymal phenotype was observed for all mammosphere-forming cell lines, indicating that CSC-proficient culture conditions co-select for mesenchymal properties, irrespectively of the parental breast cancer subtype.

Results
=======

Stem features in breast cancer cell lines grown as mammospheres
---------------------------------------------------------------

Ten breast cancer cell lines, representative of different subtypes, were used in this study. The analysis of the expression of estrogen-receptor, Vimentin, E-cadherin and cytokeratin 18 and 19 under standard growth condition (adhesion in standard medium plus 10% serum) confirmed the lineage-specific expression pattern ([Table 1](#T1){ref-type="table"}).

###### **Table 1.** Stem and epithelial/mesenchymal features of the breast cancer cell lines used in this study

  ------------------------------------------------------------------------------------------------------------------------------
  Cell line     Tumor subtype   \%\       \%\       \% CD44^+^/\   \%\        ESR1^§^   CDH1^§^   KRT18^§^   KRT19^§^   VIM^§^
                                CD24 \*   CD44 \*   CD24^-^ \*     CD133 \*                                             
  ------------- --------------- --------- --------- -------------- ---------- --------- --------- ---------- ---------- --------
  **HBL100**    Claudin-low     50 ± 15   99 ± 1    50 ± 10        10 ± 1     \-        \-        \+         \-         \+

  **MDA-157**   Claudin-low     1 ± 1     98 ± 2    98 ± 2         1 ± 1      \-        \-        ++         \-         \+

  **MDA-231**   Claudin-low     3 ± 3     98 ± 2    97 ± 3         1 ± 1      \-        \-        \-         \-         \+

  **MDA-436**   Claudin-low     8 ± 8     98 ± 2    95 ± 5         2 ± 1      \-        \-        \+         ++         \+

  **Hs578T**    Claudin-low     1 ± 1     98 ± 2    98 ± 2         2 ± 1      \-        \-        ++         \-         \+

  **MDA-468**   Basal-like      98 ± 2    98 ± 2    2 ± 1          80 ± 4     \-        \+        \+         \-         \+

  **SKBR3**     HER2-pos        99 ± 1    5 ± 2     0              2 ± 1      \-        \-        ++         ++         \-

  **BT474**     Luminal         99 ± 1    1 ± 1     0              1 ± 1      \+        \+        \+         \+         \+

  **MCF7**      Luminal         97 ± 2    92 ± 5    0              2 ± 1      ++        \+        ++         ++         \-

  **T47D**      Luminal         97 ± 2    5 ± 2     0              2 ± 1      ++        \+        ++         ++         \-
  ------------------------------------------------------------------------------------------------------------------------------

As assessed by flow cytometry analyses

^§^ As assessed by semi-quantitative PCR

The expression pattern remained unaffected when cells were grown in adhesion in standard medium or in stem medium, indicating that the growth factors present in the stem medium do not significantly impinge on the expression of these genes. Nevertheless, since we could not exclude that the shift from one medium to another may transiently perturb the expression pattern, we sought to compare the features of cells grown in adhesion (control) vs. cells grown in suspension as mammospheres, all cultured in the same stem medium.

In suspension (MS-proficient conditions), all cell lines were able to proliferate. However, MDA-157 and MDA-468 gave rise to loose aggregates and SKBR3 to tubular structures, which prevented accurate assessment of sphere-forming efficiency (SFE), and, therefore, these cell lines were excluded from the SFE analysis. High and progressively increasing SFE of secondary (M2) and tertiary (M3) spheres were observed among claudin-low cell lines. Luminal MCF7 and T47D cells formed M1 sphere at high efficiency, but the SFE decreased with passages ([Fig. 1A](#F1){ref-type="fig"}). Noteworthy, the morphology of the spheres differed among cell lines: HBL100, Hs578T, MCF7 and BT474 generated clear round spheres; T47D formed tiny round spheres; instead, MDA-436 and MDA-231 grew as clusters or grape-like spheres ([Fig. 1B](#F1){ref-type="fig"}).

![**Figure 1.** Stem properties of breast cancer cell lines. (**A**) Sphere-forming efficiency (SFE) of seven cell lines determined as described in Materials and Methods. Primary (M1, black colums), secondary (M2, gray columns) and tertiary (M3, light gray columns) SFE are reported. (**B**) Representative images of secondary spheres of HBL100, MDA-231 and MCF7. (**C**) Typical CD44/CD24 flow cytometry analyses observed in the 10 cell lines. CD44^-^/CD24^+^ phenotypes of HBL100, MDA436 and T47D cell lines were reported as examples of mixed, almost pure CD44^+^/CD24^-low^ and CD44^-^/CD24^+^ phenotypes, respectively. Percentages, referring to CD44^+^/CD24^-low^-positive cells, were determined by setting the gate on the isotype control. (**D**) CD133 flow cytometry analysis of MDA-468 cell line. Again, percentage refers to CD133-positive cells and was determined by setting the gate on the isotype control. (**E**) CD44/CD24 analysis of SKBR3 cells grown in MS-proficient conditions (M2) and in adherence (ctr) in the same-stem medium. Percentages, determined by setting the gate on CD24 high-positive parental cells, refer to CD44^+^/CD24^+^ and CD44^+^/CD24^-low^-positive cells.](cc-11-4242-g1){#F1}

The CD44^+^/CD24^-low^ phenotype recognizes a subpopulation of breast cancer stem cells endowed with tumor-initiating ability and mesenchymal phenotype.[@R16] In all but HBL100 claudin-low cell lines, a large fraction of cells displayed a CD44^+^/CD24^-low^ phenotype ([Fig. 1C](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). In HBL100, both CD44^+^/CD24^-low^ and CD133^+^ profiles were detected ([Fig. 1C](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). A CD133^+^ phenotype was displayed by MDA-468 basal-like cells ([Fig. 1D](#F1){ref-type="fig"}). Luminal and the HER2-positive SKBR3 cells were almost negative for CD44^+^/CD24^-low^ and CD133^+^ phenotypes ([Fig. 1C](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). The growth as mammospheres resulted in an expansion of the CD44^+^/CD24^low^ fraction solely in the HER2-positive SKBR3 cell line ([Fig. 1E](#F1){ref-type="fig"}).

To better characterize the stem component of the cell lines analyzed, we evaluated the expression of ALDH1A and ALDH1A3 isoforms of the ALDH1 enzyme, whose activity has been reported to characterize stem cells.[@R25]^,^[@R26] In adhesion, the ALDH1A isoform was mostly expressed by MDA-468 and BT474 ([Fig. 2A](#F2){ref-type="fig"}); the ALDH1A3 isoform was instead detected in the claudin-low HBL100 and MDA-436, the basal-like MDA-468 and the HER2-positive SKBR3 cells ([Fig. 2B](#F2){ref-type="fig"}). In mammospheres, a progressive increase in the expression of ALDH1A1 in MDA-468 and SKBR3 was detected ([Fig. 3A](#F3){ref-type="fig"}). Intriguingly, we observed that the expression of ALDH1A3 decreased with passages in seven out of 10 cell lines, although a transient increase was observed in HBL100 and BT474 ([Fig. 3B](#F3){ref-type="fig"}).

![**Figure 2.** ALDH1 expression in the breast cancer cell lines analyzed. (**A**) ALDH1A1 and (**B**) ALDH1A3 mRNA-relative expression determined by qRT-PCR. Data were normalized to three reference genes as described in Materials and Methods. Bars represent standard deviation. (**C**) SOX2 transcript determined by RT-PCR. GAPDH is reported as RNA control. NT2D1, NTera D1 cell line was used as a positive control for SOX2.](cc-11-4242-g2){#F2}

![**Figure 3.** Stem properties were modulated by MS-proficient conditions. (**A**) ALDH1A1 and (**B**) ALDH1A3 transcript levels in cells grown as primary (M1), secondary (M2) and tertiary (M3) mammospheres (gray columns) or in adherence (ctr, black columns) in the same-stem medium. Data, obtained by qRT-PCR, were normalized to three reference genes as described in Materials and Methods. Bars represent standard deviation; asterisks p \< 0.05 in one-way Anova analysis. (**C**) SOX2 protein levels, determined by western blotting, in MCF7 cells grown as primary (M1), secondary (M2) and tertiary (M3) mammospheres or in adherence (ctr) in the same-stem medium. NT2D1 is reported as a positive control. The increment of SOX2, determined by the ratio of SOX2 signal over tubulin signal (used as a loading control), is reported.](cc-11-4242-g3){#F3}

None of the cell lines analyzed expressed the embryonic pluripotency-associated genes POU5F1 and NANOG. SOX2 was expressed by MCF7 under standard conditions ([Fig. 2C](#F2){ref-type="fig"}) and was further induced in mammospheres ([Fig. 3C](#F3){ref-type="fig"}).

Mesenchymal traits in mammospheres of breast cancer cell lines
--------------------------------------------------------------

Intrinsic mesenchymal or epithelial features of the 10 breast cancer cell lines analyzed paralleled the expression pattern of the EMT-associated transcription factors. In fact, under standard growth conditions, ZEB1/2, SNAI2 and SNAI1 were all globally higher in claudin-low cells compared with the other cell types ([Fig. 4A and B](#F4){ref-type="fig"}), although each cell line expressed a distinct set of these transcription factors. TWIST1, in addition to be expressed by the claudin-low HBL100 and MDA-436 cell lines, was expressed by the luminal cell line BT474 ([Fig. 4A](#F4){ref-type="fig"}). All cell lines used tested negative for the expression of TWIST2 that was instead expressed in the control cell line FADU[@R27] (data not shown). The global low levels of expression of EMT-associated transcription factors displayed by basal-like, luminal and HER2-positive cell lines under standard conditions correlated with high levels of expression of miR200c ([Fig. 4C](#F4){ref-type="fig"}), a non coding RNA targeting ZEB1/2 and SNAI1 mRNAs.[@R28]

![**Figure 4.** EMT transcription factors and miR200c are distinctively expressed in claudin-low, basal-like, HER2-positive and luminal breast cancer cell lines. (**A**) Quantitative-RT-PCR of ZEB1 (white), ZEB2 (light gray), SNAI2 (dark gray), TWIST1 (black) in the 10 breast cancer cell lines analyzed. Relative expression of transcripts were normalized to three reference genes as described in Materials and Methods. Bars represent standard deviation. (**B**) Representative western blot analysis of SNAI1 protein levels. Blots were probed with actin for normalization. (**C**) miR200c relative levels measured by qRT-PCR as described in Materials and Methods and normalized to RNU48 as a reference control. Bars represent standard deviation.](cc-11-4242-g4){#F4}

We then examined whether mesenchymal and epithelial features were modulated when cells were grown in suspension as mammospheres. In these culture conditions, seven out of 10 cell lines displayed increased expression of the mesenchymal marker Vimentin (VIM; [Fig. 5A](#F5){ref-type="fig"}). Alongside, a significant decrease in the expression of Keratin 18 (KRT18), 19 (KRT19) and E-cadherin epithelial markers (CDH1) was observed ([Fig. 5B--D](#F5){ref-type="fig"}). Furthermore, luminal cell lines displayed a decrease in the expression of estrogen receptor-α (ESR1) and an increment in the fraction expressing CD10 (membrane metalloendopeptidase, MME), suggesting a shift toward an ER-α-negative/myoepithelial phenotype ([Fig. 5E and F](#F5){ref-type="fig"}).

![**Figure 5.** Enhanced mesenchymal features in mammospheres derived from breast cancer cell lines. Relative expression of vimentin, VIM (**A**), Keratin 18, KRT18 (**B**), Keratin 19, KRT19 (**C**), E-cadherin, CDH1 (**D**) and estrogen receptor-α, ESR1 (**E**) transcripts determined by qRT-PCR. Black columns represent control cells (ctr) grown in adherence in the stem medium; gray columns represent cells grown as primary M1, secondary M2 and tertiary M3 spheres. Data were normalized to three reference genes as described in Materials and Methods. Bars represent standard deviation, asterisks p \< 0.05 in one-way Anova analysis. (**F**) Flow cytometry analysis of CD10-expressing cells in MCF7 and BT474 cell lines grown in adherence (ctr) or as mammospheres (M3 and M2, respectively). Percentages were determined setting the gate on the isotype control.](cc-11-4242-g5){#F5}

These changes were paralleled by a global increment in the expression of EMT transcription factors ([Fig. 6](#F6){ref-type="fig"}). The pattern of expression of these genes was independent of the cell subtype, and sometimes a shift from one set of EMT transcription factors to another was observed. For instance, in MDA-157 and MDA-231, the marked induction of the ZEB members was associated with a progressive shutoff of SNAI2, particularly evident in M3 passage. A marked increment in SNAI2 and TWIST1 transcripts was instead observed in HBL100, SKBR3, MCF7 and T47D, and MDA-468 showed an increment of all but ZEB2 transcription factors ([Fig. 6](#F6){ref-type="fig"}). Taken together, these data suggest that the growth in suspension as mammospheres promotes the expansion of a population provided of mesenchymal features and characterized by the expression of a combination of EMT transcription factors, mainly SNAI2 and TWIST1.

![**Figure 6.** Modulation of ZEB1, ZEB2, SNAI2 and TWIST1 transcript levels in cells grown as primary (M1), secondary (M2) and tertiary (M3) mammospheres compared with control (cells grown in adherence in the stem medium). Heat-map represents the logarithm of the relative mRNA levels, obtained by qRT-PCR, normalized to three reference genes, as described in Materials and Methods, and referred to the control value. Red means upregulation and green downregulation as reported in the legend. Values preceded by \> indicate that the control adherent cells did not express the transcription factor and, thus, calculation was performed setting their cycle threshold value at 40 cycles which were the maximum number of PCR cycles performed. White boxes signify absence of measurable transcript expression.](cc-11-4242-g6){#F6}

Discussion
==========

An increasing amount of evidence suggests that in breast carcinomas, stemness and EMT phenotypes may be related phenomena. In fact, not only basal-like/claudin-low tumors, which frequently show mesenchymal features, display a high percentage of CD44^+^/CD24^-low^ phenotype,[@R6]^,^[@R29] but the ectopic expression of EMT-transcription factors in vitro has been proven to induce an expansion of the CSC fraction.[@R30] Instead, it remains unclear whether the reciprocal is also true, i.e., whether culture conditions that favor the selection of CSC favor also the expansion of cells undergoing epithelial to mesenchymal transition.

Here, we provide evidence that mesenchymal traits are selected along with stem features in breast cancer cells grown as mammospheres. The enrichment in stem-like cells under MS-proficient conditions was demonstrated by the increment in markers associated to stemness. In agreement with the literature data indicating that claudin-low tumors display high percentage of CD44^+^/CD24^-low^ phenotype,[@R29] we observed a clear association between CD44^+^/CD24^-low^ phenotype and mesenchymal features of the claudin-low cell lines analyzed. If the CD44^+^/CD24^-low^ population increased only in the mammospheres of the HER2-positive SKBR3 cells, in MCF7 and in BT474 cell lines an increase of the myoepithelial and stem marker CD10 was observed. The expression of CD10 characterizes CSC that give rise to metaplastic/claudin-low tumors when injected into mouse models.[@R31]^,^[@R32] Also, ALDH activity has been associated to CSC, and, accordingly, we observed that ALDH1A1, whose expression has been reported to correlate with disease-free survival, high-grade and lymph node positivity,[@R33]^-^[@R35] increased in the mammospheres of two cell lines. In contrast to what was originally proposed, ALDH1A3 expression inversely correlates with stemness, as it peaks during the commitment of breast stem cells to the luminal lineage and in the luminal progenitors.[@R36] Accordingly, we observed that ALDH1A3 transcript levels, which well-reflected the aldefluor activity previously reported for the cell lines analyzed,[@R26]^,^[@R37]^,^[@R38] decreased in the long-term mammospheres irrespective of the breast cancer subtype of origin.

Finally, although the analysis of pluripotency-associated genes indicated a minor role for these factors in the stem phenotype of the breast cancer cell lines, SOX2 seemed to be involved in the promotion of stem features in MCF7 cells.

Under MS-proficient conditions, we observed upregulation of mesenchymal markers and downregulation epithelial factors and estrogen-receptor. In cells grown as mammospheres, the gain of mesenchymal traits was paralleled by the rise in EMT-transcription factors, SNAI2 and TWIST1 in particular. We can rule out that the observed selection of EMT features may be the result of a shift induced by the stem-cell culture cytokines included in the stem medium, because all analyses were done by comparing cells grown in different conditions (in adhesion vs. in suspension as mammospheres) but in the very same medium.

The enrichment in mesenchymal traits along with stem features may be explained by either a selection of a pre-existing minute subpopulation of cells with mesenchymal features or by de novo induction of EMT. It has been recently demonstrated that breast cell lines, including luminal cell lines, contain a small fraction of cells expressing basal-like and claudin-low markers and EMT transcription factors.[@R39] On the other hand, it has been shown that that three-dimensional cultures may affect cell signaling pathways,[@R40] and loss of cell polarity and cell-cell interactions may promote epithelial-mesenchymal transition.[@R41]^,^[@R42] Intriguingly, we observed that short-term mammospheres of MCF7 cells display gain of mesenchymal features but fail to enrich in the CD44^+^/CD24^-/low^ fraction, which Gutilla and colleagues reported to occur in long-term mammospheres.[@R43] This result suggests that the shift toward a mesenchymal phenotype may precede the gain of stem features. In this scenario, the gain of stem features would be the outcome, rather than the cause, of an EMT reprogramming, which is somehow in agreement with what observed in BRCA1-mutated tumors (reviewed in ref. [@R44]).

Taken together, our data suggest that MS-proficient conditions select for cells with mesenchymal traits. This observation is not trivial. In fact, phenomena of transdifferentiation may result in chemoresistance and tumor progression. For instance, the gain of mesenchymal features in mammospheres derived from luminal tumors correlates with downregulation of ER-α and, hence, with resistance to anti-ER therapies.[@R39] Thus, the screening for new compounds should ideally be performed in culture conditions that well-represent these phenomena, and mammosphere culture conditions have the potential to allow the exploitation of novel therapeutic approaches.[@R45]^,^[@R46]

In summary, the demonstration that MS-proficient conditions allows the expansion of cell populations displaying the two major features of highly aggressive breast tumors (stemness and EMT) supports the adoption of mammospheres as in vitro model for the development and validation of novel and more effective therapeutic approaches.

Materials and Methods
=====================

Cell lines and standard culture conditions
------------------------------------------

A panel of 10 human breast cancer cell lines (MDAMB-157, MDAMB-231, MDAMB-436, MDAMB-468, MCF7, T47D, BT474, SKBR3) was purchased from the American Type Culture Collection (ATCC) and Interlab Cell Line Collection-Genova (Hs578T, HBL100). All cell lines were validated for short tandem repeat profiling.

MDAMB-157, MDAMB-231, MDAMB-436, MDAMB-468, Hs578T, HBL100, T47D, SKBR3 cell lines were cultured in EMEM (Lonza) supplemented with 10% fetal bovine serum (Gibco, Invitrogen), non-essential amino acids (Gibco, Invitrogen) and antibiotics. MCF7 and BT474 were cultered in RPMI (Lonza) supplemented with 10% FBS and antibiotics.

MDAMB-157, MDAMB-231, MDAMB-436 and MDAMB-468 are referred in this paper as MDA-157, MDA-231, MDA-436 and MDA-468, respectively.

Mammosphere culture conditions (MS-proficient condition) and Sphere-forming eficiency (SFE)
-------------------------------------------------------------------------------------------

Single-cell suspensions derived from monolayer cultures were maintained in a serum-free "stem medium" consisting of DMEM F-12 medium (Gibco) supplemented with 4 ug/ml heparin (Sigma), 0,6% glucose, 0,1% NaHCO3, 100 ug/ml apotransferrin, 25 ug/ml insulin, 9 ug/ml putrescine (1--4 diaminobutane dihydrochloride) (Sigma) and 3 × 10--4 M sodium selenite (Sigma) in ultra-low attachment plates (Corning). Every other day, culture medium was enriched with fresh 20 ng/ml EGF and 10 ng/ml bFGF (Peprotech). Mammospheres were collected by centrifugation every 6--12 d and dissociated enzymatically (5 min in 0,05% Trypsin/EDTA) or mechanically by pipetting. The obtained single cells were re-plated for secondary and tertiary cultures and collected for RNA and protein.

For SFE analysis, single-cell suspensions derived from monolayer cultures were plated at a density of 2,500 cells/well into 96-well ultra-low attachment plates (Corning). Cells were maintained in the medium conditions mentioned above and were allowed to form spheres up to 10 d. The number of spheres (\> 50 cells/sphere) per well was then counted and expressed as ratio of speres/1,000 plated cells (SFE). Mammospheres were collected by centrifugation and mechanically or enzymatically dissociated. Single cells obtained were counted and re-seeded for secondary and tertiary cultures.

Flow cytometry
--------------

Monolayer cultured cells and mammospheres were detached in PBS 2 mM EDTA, washed in cold PBS, counted and resuspended at 1 × 10^6^ cells/100 μl in blocking solution (PBS 10% Rabbit Serum, Dako). Cells were labeled with anti-human CD24-PE/Cy7 (BioLegend), CD24-PE (BD, Biosciences), CD44-FITC (BD, Biosciences), CD133/1-PE (Miltenyi Biotec), CD10-PECy5 (BD, Biosciences) or isotype controls according to the suppliers' protocols. Then, cell samples were washed, resuspended in cold PBS 2 mM EDTA, examined on FACSCanto (BD, Biosciences) or Cytomics FC500 (Beckman Coulter) and analyzed by FACSDiva software (BD, Biosciences) or CXP Software (Beckman Coulter), respectively.

RNA extraction, RT-PCR and qRT-PCR
----------------------------------

Total RNA was extracted from cells using Trizol (Invitrogen). mRNAs were reverse transcribed into cDNA with SuperScript II Reverse Transcriptase (Invitrogen) and random primers in according with the supplier's protocol. For SOX2 analysis, total RNA was reverse transcribed using a modified poly T oligo (5'GAACGAGACGACGACAGACTTTTTTTTTTTTTTTTTTTTTVVN).[@R47] RT-PCR was performed using cDNA in a 35 cycles of PCR amplification using Taq Polymerase kit (Promega).

Quantitative RT-PCR (qRT-PCR), using gene-specific primers, was performed in triplicate with SsoFast EvaGreen Supermix (BioRad) and the CFX96 Real-Time System (Bio-Rad). Relative expression levels were normalized to controls by using the comparative Ct (ΔΔCt) method and the geometric average of a set of three housekeeping genes (GAPDH, B2M and RN18S1) by the Bio-Rad CFX manager software. Specific primer pairs have been reported in the [**Table S1**](#SUP1){ref-type="supplementary-material"}. For each gene, three experiments were performed.

Variation in EMT-transcription factor levels was performed using ΔΔCt method reported to the control cells grown in adherence in the same stem medium. Logarithm of relative mRNA levels was then performed. In the case control cells did not express an EMT-transcription factor, calculation was performed, setting their Ct value at 40 cycles, which is the maximum number of cycles for PCR, and values were reported as major of (\>).

For miR200c analysis, RNA was converted into cDNA and amplified in the qRT-PCR by using TaqMan-specific kits for miR200c or for RNU48, as a normalizer, (Applied Biosystems). Again, relative miRNA expression was determined by the ΔΔCt method. Statistical differences between means were evaluated using one-way analysis of variance (Anova) test.

Western blot analysis
---------------------

Western blotting was performed on cell protein lysates (50 mM Tris, pH 7.6, 250 mM NaCl, 0,2% Triton X-100, 0,3% NP40, 2 nM EGTA, 2 nM EDTA, 0.1% P-40, complete protease inhibitor cocktail Roche Molecular Biochemicals) using mouse antibodies reacting to human SOX2 (R&D Systems), actin (Santacruz) and rabbit antibodies to human SNAI1 (Cell Signaling) and β-tubulin (Santacruz). Immunoreactivity was detected with anti-mouse and anti-rabbit secondary antibodies HRP-labeled (PerkinElmer) using Western Lightning^™^ Chemiluminescence Reagent Plus (PerkinElmer) by the imaging analyzer Chemidoc XRS+ (Biorad). Protein expression was analyzed using the ImageLab imaging software (Bio-Rad).
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